标题
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
作者
关键词
-
出版物
Expert Review of Gastroenterology & Hepatology
Volume 14, Issue 5, Pages 311-321
出版商
Informa UK Limited
发表日期
2020-04-03
DOI
10.1080/17474124.2020.1748498
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Will vitamin E be the hope of patients with NASH and advanced fibrosis? – the reliability is worth discussing
- (2019) He Jian et al. HEPATOLOGY
- Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease
- (2019) Tawfik Khoury et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
- (2019) Dan-Ying Zhang et al. Drug Design Development and Therapy
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Phase 3 drug pipelines in the treatment of NASH
- (2019) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- (2019) Juliette Mouries et al. JOURNAL OF HEPATOLOGY
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression
- (2019) Aline Gottlieb et al. Cells
- Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3
- (2019) Yuan-Yuan Fan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- Insights into the role of hepatocyte PPARα activity in response to fasting
- (2018) Marion Régnier et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial
- (2018) Paola Portillo-Sanchez et al. Journal of Diabetes
- Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
- (2018) Eduardo Vilar-Gomez et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- Treatment of NAFLD with diet, physical activity and exercise
- (2017) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III
- (2017) M. Ghosh Laskar et al. JOURNAL OF INTERNAL MEDICINE
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study
- (2016) Zoltan Pataky et al. DIGESTIVE DISEASES AND SCIENCES
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- The Natural Course of Non-Alcoholic Fatty Liver Disease
- (2016) Luis Calzadilla Bertot et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease
- (2016) Hui-Jie Zhang et al. JAMA Internal Medicine
- Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage
- (2015) Liangpeng Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs Population
- (2015) Sahil Mittal et al. Clinical Gastroenterology and Hepatology
- Bile Acids as Hormones: The FXR-FGF15/19 Pathway
- (2015) Steven A. Kliewer et al. DIGESTIVE DISEASES
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- (2015) Stuart McPherson et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- FXR is a molecular target for the effects of vertical sleeve gastrectomy
- (2014) Karen K. Ryan et al. NATURE
- Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2014) Yoshio Sumida WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion
- (2013) Nisanne S. Ghonem et al. HEPATOLOGY
- Positive regulation of osteogenesis by bile acid through FXR
- (2013) Sun Wook Cho et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease
- (2013) Marno C. Ryan et al. JOURNAL OF HEPATOLOGY
- Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice
- (2013) Thomas Gautier et al. JOURNAL OF LIPID RESEARCH
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
- (2013) Siddharth Verma et al. LIVER INTERNATIONAL
- Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial
- (2013) Carly Eckard et al. Therapeutic Advances in Gastroenterology
- Validation of the non-alcoholic fatty liver disease activity score
- (2011) M. Hjelkrem et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
- (2011) Matthew J. Potthoff et al. Cell Metabolism
- Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects
- (2011) Sven Haufe et al. HEPATOLOGY
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- Chemokines as Immune Mediators of Liver Diseases Related to the Metabolic Syndrome
- (2010) Marie-Luise Berres et al. DIGESTIVE DISEASES
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
- (2010) Giovanni Musso et al. HEPATOLOGY
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- (2010) Elizabeth M. Brunt et al. HEPATOLOGY
- Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease
- (2010) Ravi Juluri et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
- (2009) Valérie Paradis et al. HEPATOLOGY
- FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action
- (2009) Dong-Ju Shin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia
- (2009) Yanqiao Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease
- (2009) Maria Cristina Elias et al. NUTRITION
- Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists
- (2008) Songwen Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now